1 Boland, C. R. et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer research 58, 5248-5257 (1998).
2 Lynch, H. T. et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clinical genetics 76, 1-18, doi:10.1111/j.1399-0004.2009.01230.x (2009).
3 Dolcetti, R. et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. The American journal of pathology 154, 1805-1813, doi:10.1016/S0002-9440(10)65436-3 (1999).
4 Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116-120, doi:10.1038/nature24673 (2017).
5 Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413, doi:10.1126/science.aan6733 (2017).
6 Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine 372, 2509-2520, doi:10.1056/NEJMoa1500596 (2015).
7 Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nature medicine 19, 1423-1437, doi:10.1038/nm.3394 (2013).
8 Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Cancer-related inflammation and treatment effectiveness. The Lancet. Oncology 15, e493-503, doi:10.1016/S1470-2045(14)70263-3 (2014).
9 Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute 106, dju124, doi:10.1093/jnci/dju124 (2014).
10 Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. The Journal of experimental medicine 217, doi:10.1084/jem.20190354 (2020).
11 Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature medicine 24, 541-550, doi:10.1038/s41591-018-0014-x (2018).
12 Jiang, X. et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Molecular cancer 18, 10, doi:10.1186/s12943-018-0928-4 (2019).
13 Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical reviews in oncology/hematology 88, 218-230, doi:10.1016/j.critrevonc.2013.03.010 (2013).
14 Ameratunga, M. et al. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. European journal of cancer 89, 56-63, doi:10.1016/j.ejca.2017.11.012 (2018).
15 Sacdalan, D. B., Lucero, J. A. & Sacdalan, D. L. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. OncoTargets and therapy 11, 955-965, doi:10.2147/OTT.S153290 (2018).
16 Bredius, R. G. et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 83, 624-630 (1994).
17 Berger, M. & Medof, M. E. Increased expression of complement decay-accelerating factor during activation of human neutrophils. The Journal of clinical investigation 79, 214-220, doi:10.1172/JCI112786 (1987).
18 McDonald, B. et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. The Journal of experimental medicine 205, 915-927, doi:10.1084/jem.20071765 (2008).
19 He, W. Z. et al. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value. Journal of Cancer 9, 3093-3100, doi:10.7150/jca.26669 (2018).
20 Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet. Oncology 18, 1182-1191, doi:10.1016/S1470-2045(17)30422-9 (2017).
21 Akbay, E. A. et al. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 12, 1268-1279, doi:10.1016/j.jtho.2017.04.017 (2017).
22 Faget, J. et al. Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer. Cell reports 21, 3190-3204, doi:10.1016/j.celrep.2017.11.052 (2017).
23 Furumaya, C., Martinez-Sanz, P., Bouti, P., Kuijpers, T. W. & Matlung, H. L. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. Frontiers in immunology 11, 2100, doi:10.3389/fimmu.2020.02100 (2020).
24 Wculek, S. K. & Malanchi, I. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528, 413-417, doi:10.1038/nature16140 (2015).
25 Liu, Y. et al. Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer cell 30, 243-256, doi:10.1016/j.ccell.2016.06.021 (2016).
26 Wang, T. T. et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut 66, 1900-1911, doi:10.1136/gutjnl-2016-313075 (2017).
27 Giese, M. A., Hind, L. E. & Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. Blood 133, 2159-2167, doi:10.1182/blood-2018-11-844548 (2019).
28 Qin, H. et al. Targeting tumor-associated myeloid cells for cancer immunotherapy. Oncoimmunology 4, e983961, doi:10.4161/2162402X.2014.983761 (2015).
29 Zhang, P. et al. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 116, 23714-23723, doi:10.1073/pnas.1906346116 (2019).
30 Van Coillie, S., Wiernicki, B. & Xu, J. Molecular and Cellular Functions of CTLA-4. Advances in experimental medicine and biology 1248, 7-32, doi:10.1007/978-981-15-3266-5_2 (2020).
31 Eri, R., Kodumudi, K. N., Summerlin, D. J. & Srinivasan, M. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflammatory bowel diseases 14, 458-470, doi:10.1002/ibd.20344 (2008).
32 Agraz-Cibrian, J. M. et al. Impaired neutrophil extracellular traps and inflammatory responses in the peritoneal fluid of patients with liver cirrhosis. Scandinavian journal of immunology 88, e12714, doi:10.1111/sji.12714 (2018).
33 Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in oncology 8, 86, doi:10.3389/fonc.2018.00086 (2018).
34 Zhang, Y., Lee, C., Geng, S. & Li, L. Enhanced tumor immune surveillance through neutrophil reprogramming due to Tollip deficiency. JCI insight 4, doi:10.1172/jci.insight.122939 (2019).
35 Anfray, C., Ummarino, A., Andon, F. T. & Allavena, P. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses. Cells 9, doi:10.3390/cells9010046 (2019).
36 Jiang, T. et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung cancer 130, 76-83, doi:10.1016/j.lungcan.2019.02.009 (2019).
37 Shaul, M. E. & Fridlender, Z. G. Tumour-associated neutrophils in patients with cancer. Nature reviews. Clinical oncology 16, 601-620, doi:10.1038/s41571-019-0222-4 (2019).
38 Fan, X. et al. Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. Frontiers in cell and developmental biology 9, 638312, doi:10.3389/fcell.2021.638312 (2021).
39 Corti, F. et al. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European journal of cancer 150, 155-167, doi:10.1016/j.ejca.2021.03.043 (2021).
40 Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Journal for immunotherapy of cancer 6, 74, doi:10.1186/s40425-018-0383-1 (2018).
41 Liu, G. C. et al. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. Journal of the National Cancer Institute 110, 975-984, doi:10.1093/jnci/djy004 (2018).
42 Liu, C. et al. A portable and cost-effective microfluidic system for massively parallel single-cell transcriptome profiling. bioRxiv, 818450, doi:10.1101/818450 (2019).
43 Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21, doi:10.1093/bioinformatics/bts635 (2013).
44 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnology 36, 411-420, doi:10.1038/nbt.4096 (2018).
45 Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401, doi:10.1126/science.1254257 (2014).
46 Vento-Tormo, R. et al. Single-cell reconstruction of the early maternal–fetal interface in humans. Nature563, 347-353, doi:10.1038/s41586-018-0698-6 (2018).